See more : Gabetti Property Solutions S.p.A. (GAB.MI) Income Statement Analysis – Financial Results
Complete financial analysis of GT Biopharma, Inc. (GTBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GT Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Luen Wong Group Holdings Limited (8217.HK) Income Statement Analysis – Financial Results
- Mobilicom Limited (MOBBW) Income Statement Analysis – Financial Results
- BrightRock Gold Corp. (BRGC) Income Statement Analysis – Financial Results
- PT Multi Agro Gemilang Plantation Tbk (MAGP.JK) Income Statement Analysis – Financial Results
- Hiraki Co.,Ltd. (3059.T) Income Statement Analysis – Financial Results
GT Biopharma, Inc. (GTBP)
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.00K | 61.00K | 368.00K | 342.00K | 26.00K | 11.00K | 48.00K | 1.14M | 6.05M | 5.78M | 2.50M | 2.36M | 2.74M | 2.05M | 2.97M | 3.54M | 7.17M | 5.10M | 5.10M | 4.90M | 5.10M | 3.50M | 3.00M | 2.80M | 2.70M | 4.80M | 5.10M | 3.20M | 2.30M | 3.00M | 2.40M | 4.16M | 3.83M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 57.00K | 226.00K | 94.00K | 48.00K | 65.00K | 50.00K | 909.00K | 3.26M | 3.08M | 1.35M | 1.22M | 1.50M | 1.14M | 2.43M | 2.62M | 5.05M | 2.60M | 2.00M | 1.60M | 1.60M | 1.50M | 1.20M | 1.20M | 1.00M | 1.90M | 2.10M | 1.20M | 500.00K | 1.10M | 900.00K | 2.33M | 2.28M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -4.00K | -7.00K | -2.00K | -1.00K | 25.00K | 4.00K | 142.00K | 248.00K | -22.00K | -54.00K | -2.00K | 234.00K | 2.79M | 2.69M | 1.15M | 1.15M | 1.24M | 910.00K | 538.00K | 924.00K | 2.11M | 2.50M | 3.10M | 3.30M | 3.50M | 2.00M | 1.80M | 1.60M | 1.70M | 2.90M | 3.00M | 2.00M | 1.80M | 1.90M | 1.50M | 1.83M | 1.55M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 92.59% | 6.56% | 38.59% | 72.51% | -84.62% | -490.91% | -4.17% | 20.47% | 46.09% | 46.61% | 46.14% | 48.56% | 45.40% | 44.39% | 18.13% | 26.10% | 29.50% | 49.02% | 60.78% | 67.35% | 68.63% | 57.14% | 60.00% | 57.14% | 62.96% | 60.42% | 58.82% | 62.50% | 78.26% | 63.33% | 62.50% | 43.99% | 40.47% |
| Research & Development | 6.47M | 8.81M | 9.59M | 485.00K | 1.67M | 9.07M | 1.07M | 975.00K | 1.00M | 0.00 | 0.00 | 0.00 | 17.00K | 179.00K | 0.00 | 44.00K | 1.04M | 708.00K | 499.00K | 236.00K | 369.00K | 463.00K | 762.00K | 1.91M | 2.40M | 4.40M | 4.30M | 4.90M | 4.30M | 1.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 590.00K | 400.00K |
| General & Administrative | 0.00 | 0.00 | 47.92M | 6.28M | 9.79M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 935.00K | 3.36M | 3.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.13M | 1.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 400.00K | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.11M | 12.45M | 47.92M | 6.28M | 9.79M | 12.49M | 134.50M | 8.40M | 7.95M | 2.40M | 935.00K | 3.76M | 3.89M | 2.26M | 1.15M | 1.40M | 2.87M | 4.65M | 2.34M | 2.03M | 1.65M | 1.26M | 2.29M | 3.30M | 3.29M | 3.60M | 2.60M | 2.80M | 3.30M | 1.70M | 3.40M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.13M | 1.19M |
| Other Expenses | 0.00 | 0.00 | -242.76K | -12.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 155.00K | 0.00 | 0.00 | 0.00 | 942.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.40M | 935.00K | 3.76M | 3.91M | 2.44M | 1.15M | 1.45M | 3.90M | 5.36M | 2.84M | 2.26M | 2.02M | 1.72M | 3.99M | 5.65M | 6.52M | 9.60M | 8.10M | 9.10M | 9.00M | 4.00M | 3.50M | 2.10M | 2.20M | 2.40M | 2.50M | 2.10M | 1.60M | 2.50M | 2.30M | 1.72M | 1.60M |
| Cost & Expenses | 13.58M | 21.26M | 57.52M | 6.76M | 11.46M | 21.55M | 135.57M | 9.37M | 8.95M | 2.46M | 1.16M | 3.86M | 3.95M | 2.51M | 1.20M | 2.35M | 7.17M | 8.45M | 4.19M | 3.48M | 3.51M | 2.86M | 6.42M | 8.27M | 11.58M | 12.20M | 10.10M | 10.70M | 10.60M | 5.50M | 4.70M | 3.30M | 3.20M | 4.30M | 4.60M | 3.30M | 2.10M | 3.60M | 3.20M | 4.05M | 3.88M |
| Interest Income | 567.00K | 292.00K | 38.00K | 3.32K | 2.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 0.00 | 52.00K | 80.00K | 110.00K | 1.00K | 1.00K | 7.00K | 29.00K | 180.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 8.00K | 718.00K | 3.32M | 2.13M | 9.12M | 8.60M | 6.56M | 17.04M | 5.15M | 1.20M | 1.65M | 556.00K | 513.00K | 1.14M | 1.66M | 1.01M | 2.16M | 26.00K | 101.00K | 14.00K | 18.00K | 14.00K | 90.00K | 0.00 | 300.00K | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 290.00K | 210.00K |
| Depreciation & Amortization | 13.58M | 21.26M | 57.52M | 4.00K | 4.00K | 7.00K | 2.00K | 1.00K | 2.00K | 22.00K | 2.00K | 3.00K | 23.00K | 31.00K | 55.00K | 251.00K | 893.00K | 301.00K | 154.00K | 785.00K | 177.00K | 282.00K | 412.00K | 443.00K | 838.00K | 1.60M | 1.20M | 1.40M | 1.40M | 600.00K | 100.00K | -300.00K | -300.00K | -300.00K | -300.00K | -200.00K | 100.00K | -200.00K | -300.00K | 790.00K | 480.00K |
| EBITDA | 5.98M | 0.00 | 0.00 | -24.98M | -11.45M | -250.06M | -135.57M | -9.37M | -8.93M | -2.37M | -791.00K | -3.61M | -3.12M | -2.45M | -1.06M | -822.00K | -223.00K | -2.37M | -1.54M | -1.72M | -596.00K | -529.00K | -3.04M | -4.28M | -3.57M | -5.50M | -3.80M | -4.50M | -4.10M | -1.40M | -1.60M | -800.00K | -800.00K | 200.00K | 200.00K | -300.00K | 200.00K | -800.00K | -1.10M | 890.00K | 430.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,055.56% | -3,891.80% | -602.17% | -1,026.61% | -15,019.23% | -22,418.18% | -2,285.42% | -83.99% | -48.64% | -42.64% | -1.56% | 47.08% | -22.04% | -25.80% | -68.80% | -120.99% | -50.65% | -113.73% | -76.47% | -89.80% | -15.69% | 62.86% | -60.00% | -28.57% | -29.63% | 4.17% | 3.92% | -9.38% | 13.04% | -26.67% | -45.83% | 21.39% | 11.23% |
| Operating Income | -13.58M | -21.26M | -57.52M | -6.76M | -16.06M | -250.07M | -135.57M | -9.37M | -8.93M | -2.40M | -793.00K | -3.51M | -3.93M | -2.50M | -1.16M | -1.21M | -1.12M | -2.67M | -3.19M | -1.72M | -773.00K | -811.00K | -3.45M | -4.73M | -4.41M | -7.10M | -5.00M | -5.80M | -5.50M | -2.00M | -1.70M | -500.00K | -500.00K | 500.00K | 500.00K | -100.00K | 200.00K | -600.00K | -800.00K | 100.00K | -50.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,062.96% | -3,927.87% | -215.49% | -1,027.49% | -15,107.69% | -22,700.00% | -2,408.33% | -105.95% | -18.45% | -46.23% | -127.71% | -72.72% | -28.21% | -39.56% | -116.34% | -133.50% | -61.55% | -139.22% | -98.04% | -118.37% | -107.84% | -57.14% | -56.67% | -17.86% | -18.52% | 10.42% | 9.80% | -3.13% | 8.70% | -20.00% | -33.33% | 2.40% | -1.31% |
| Total Other Income/Expenses | 5.98M | 373.00K | -498.00K | -21.53M | -22.59M | -9.12M | -7.68M | 19.14M | -12.53M | -21.11M | 229.00K | -1.75M | 228.00K | -498.00K | -1.09M | -1.50M | 1.49M | -1.98M | 82.00K | -937.00K | -5.00K | -11.00K | -999.00K | 0.00 | 57.00K | 300.00K | 100.00K | 0.00 | -3.30M | -3.60M | 200.00K | 300.00K | 300.00K | 300.00K | 300.00K | 200.00K | 200.00K | 200.00K | 300.00K | 290.00K | 210.00K |
| Income Before Tax | -7.60M | -20.88M | -58.01M | -28.30M | -38.65M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -564.00K | -5.26M | -3.70M | -3.00M | -2.25M | -2.71M | 546.00K | 4.82M | -3.11M | -2.66M | -778.00K | -822.00K | -4.45M | 0.00 | -4.35M | -6.80M | -4.90M | 0.00 | -8.80M | -5.60M | -1.50M | -200.00K | -200.00K | 800.00K | 800.00K | 100.00K | 400.00K | -400.00K | -500.00K | 390.00K | 160.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -153.26% | -1,538.30% | -14,230.77% | -27,227.27% | -4,679.17% | -237.01% | 9.03% | 83.45% | -124.43% | -112.35% | -28.39% | -40.10% | -150.00% | 0.00% | -60.75% | -133.33% | -96.08% | 0.00% | -172.55% | -160.00% | -50.00% | -7.14% | -7.41% | 16.67% | 15.69% | 3.13% | 17.39% | -13.33% | -20.83% | 9.38% | 4.18% |
| Income Tax Expense | 0.00 | -381.00K | 680.00K | 3.32M | 2.13M | -228.52M | 7.68M | -30.41M | 17.04M | 5.15M | -292.00K | 1.56M | 556.00K | 513.00K | 1.14M | 77.00K | 75.00K | 120.00K | 2.00K | 1.54M | 13.00K | 0.00 | 42.00K | -42.00K | 85.00K | 0.00 | 200.00K | 200.00K | 3.40M | 3.60M | -200.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 180.00K | 70.00K |
| Net Income | -7.60M | -20.50M | -58.69M | -31.62M | -40.78M | -259.19M | -143.25M | 21.03M | -32.73M | -23.49M | -501.00K | -5.17M | -3.70M | -3.00M | -2.25M | -5.01M | 471.00K | -4.94M | -3.11M | -2.66M | -791.00K | -822.00K | -3.50M | -4.68M | -4.50M | -7.10M | -5.20M | -6.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 900.00K | 700.00K | 100.00K | 300.00K | -400.00K | -300.00K | 420.00K | 150.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -121,207.41% | -38,506.56% | -136.14% | -1,511.99% | -14,230.77% | -27,227.27% | -4,679.17% | -437.97% | 7.79% | -85.53% | -124.51% | -112.35% | -28.87% | -40.10% | -117.76% | -132.32% | -62.74% | -139.22% | -101.96% | -122.45% | -174.51% | -160.00% | -50.00% | -10.71% | -7.41% | 18.75% | 13.73% | 3.13% | 13.04% | -13.33% | -12.50% | 10.10% | 3.92% |
| EPS | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| EPS Diluted | -5.64 | -19.30 | -62.54 | -216.29 | -361.49 | -87.70 | -145.22 | 4.39K | -69.63K | -50.62K | -1.12K | -13.19K | -17.54K | -25.60K | -43.19K | -139.06K | 13.08K | -145.29K | -94.21K | -83.00K | -39.55K | -117.43K | -499.29K | -669.14K | -749.17K | -1.18M | -1.30M | -3.00M | -8.90M | -5.60M | -1.50M | -300.00K | -200.00K | 1.08M | 956.34K | 191.27K | 382.54K | -400.00K | -300.00K | 0.01 | 0.00 |
| Weighted Avg Shares Out | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
| Weighted Avg Shares Out (Dil) | 1.35M | 1.06M | 938.52K | 146.17K | 112.80K | 2.96M | 986.42K | 4.79K | 470.00 | 464.00 | 449.00 | 392.00 | 211.00 | 117.00 | 52.00 | 36.00 | 36.00 | 34.00 | 33.00 | 32.00 | 20.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 30.58M | 30.58M |
Are Penny Stocks Worth It? 3 Cheap Stocks To Watch Before June 2021
GameStop (NYSE:GME) Is Surging Bringing Validity To Countless Penny Stocks Right Now The post Are Penny Stocks Worth It? 3 Cheap Stocks To Watch Before June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Trading Penny Stocks? 3 Biotech Stocks To Watch Before June 2021
Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?
Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021
Penny stocks that left the nest in 2021 To Watch Right Now The post Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Penny Stocks To Watch Right Now That Analysts Are Bullish On
Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET
BEVERLY Hills, Calif., May 18, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology, TriKE™, for the...
GT Biopharma Reports First Quarter 2021 Results
BEVERLY HILLS, Calif., May 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic...
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know
OXIS International Inc. (GTBP) closed the most recent trading day at $12.51, moving +1.54% from the previous trading session.
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
Former Penny Stocks To Watch Making Their Mark In 2021
These penny stocks hit it out of the park in 2021 & continue to climb in May. The post Former Penny Stocks To Watch Making Their Mark In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information...
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates
BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:… The post GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates appeared first on Penny...
Source: https://incomestatements.info
Category: Stock Reports